PolyPeptide Group AG
PPGN
Company Profile
Business description
PolyPeptide Group AG is an independent contract development and manufacturing organization (CDMO) focused on peptides and oligonucleotides employed as an active pharmaceutical ingredients (APIs) and used as intermediates in therapeutic products. The company derives majority of its revenue from Europe and Asia.
Contact
Neuhofstrasse 24
Baar
Zug6340
CHET: +41 435020580
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 December 2025
Employees
1,366
Stocks News & Analysis
stocks
Tesla: Shares down despite record deliveries
We think the positive third-quarter numbers will be largely offset by a weak fourth quarter.
stocks
ASX listed share dominates their industry
Shares are currently fairly valued with a Wide Moat rating.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,288.10 | 53.60 | 0.58% |
| CAC 40 | 8,081.54 | 24.91 | 0.31% |
| DAX 40 | 24,378.80 | 43.76 | -0.18% |
| Dow JONES (US) | 46,758.28 | 238.56 | 0.51% |
| FTSE 100 | 9,491.25 | 63.52 | 0.67% |
| HKSE | 27,140.92 | 146.20 | -0.54% |
| NASDAQ | 22,780.51 | 63.54 | -0.28% |
| Nikkei 225 | 45,769.50 | 832.77 | 1.85% |
| NZX 50 Index | 13,514.09 | 62.33 | 0.46% |
| S&P 500 | 6,715.79 | 0.44 | 0.01% |
| S&P/ASX 200 | 8,987.40 | 50.80 | 0.57% |
| SSE Composite Index | 3,882.78 | 20.25 | 0.52% |